A US pharmaceutical company executive who became a symbol of industry greed is about to stand trial for securities fraud.

But, given Martin Shkreli's notoriety for price gouging, the court has struggled to find jurors who can be impartial.

So far more than 250 potential jurors have been dismissed because they have strong objections to the defendant.

Al Jazeera's Kristen Saloomey reports from New York.